Jose M Trigo1, Dina Lagzdins1, Jürgen Rehm2, Peter Selby3, Islam Gamaleddin4, Benedikt Fischer5, Allan J Barnes6, Marilyn A Huestis6, Bernard Le Foll7. 1. Translational Addiction Research Laboratory, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Canada. 2. Social and Epidemiological Research Department, CAMH, Toronto, Canada; Addiction Policy, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada; Institute of Medical Science, University of Toronto, Faculty of Medicine, Toronto, Canada; Department of Psychiatry, University of Toronto, Canada; Institute of Clinical Psychology and Psychotherapy & Center of Clinical Epidemiology and Longitudinal Studies (CELOS), Technische Universität Dresden, Dresden, Germany. 3. Department of Psychiatry, University of Toronto, Canada; Addictions Division, CAMH, Toronto, Canada; Department of Family and Community Medicine, University of Toronto, Canada. 4. Translational Addiction Research Laboratory, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Canada; Department of Medical Sciences, Institute of Environmental Studies and Research, Ain Shams University, Cairo, Egypt; Directorate of Poison Control Centres, MOH, Riyadh, Saudi Arabia. 5. Social and Epidemiological Research Department, CAMH, Toronto, Canada; Department of Psychiatry, University of Toronto, Canada; Centre for Applied Research in Mental Health & Addiction, Faculty of Health Sciences, Simon Fraser University, Vancouver, Canada. 6. Chemistry and Drug Metabolism, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), Baltimore, USA. 7. Translational Addiction Research Laboratory, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Canada; Addictions Division, CAMH, Toronto, Canada. Electronic address: bernard.lefoll@camh.ca.
Abstract
BACKGROUND: There is currently no pharmacological treatment approved for cannabis dependence. In this proof of concept study, we assessed the feasibility/effects of fixed and self-titrated dosages of Sativex (1:1, Δ(9)-tetrahydrocannabinol (THC)/cannabidiol (CBD)) on craving and withdrawal from cannabis among nine community-recruited cannabis-dependent subjects. METHODS: Participants underwent an 8-week double-blind placebo-controlled trial (an ABACADAE design), with four smoke as usual conditions (SAU) (A) separated by four cannabis abstinence conditions (B-E), with administration of either self-titrated/fixed doses of placebo or Sativex (up to 108 mg THC/100 mg CBD). The order of medication administration during abstinence conditions was randomized and counterbalanced. Withdrawal symptoms and craving were assessed using the Cannabis Withdrawal Scale (CWS), Marijuana Withdrawal Checklist (MWC) and Marijuana Craving Questionnaire (MCQ). Medication use was assessed during the study by means of self-reports, vial weight control, toxicology and metabolite analysis. Cannabis use was assessed by means of self-reports. RESULTS: High fixed doses of Sativex were well tolerated and significantly reduced cannabis withdrawal during abstinence, but not craving, as compared to placebo. Self-titrated doses were lower and showed limited efficacy as compared to high fixed doses. Participants reported a significantly lower "high" following Sativex or placebo as compared to SAU conditions. Cannabis/medication use along the study, as per self-reports, suggests compliance with the study conditions. CONCLUSIONS: The results found in this proof of concept study warrant further systematic exploration of Sativex as a treatment option for cannabis withdrawal and dependence.
RCT Entities:
BACKGROUND: There is currently no pharmacological treatment approved for cannabis dependence. In this proof of concept study, we assessed the feasibility/effects of fixed and self-titrated dosages of Sativex (1:1, Δ(9)-tetrahydrocannabinol (THC)/cannabidiol (CBD)) on craving and withdrawal from cannabis among nine community-recruited cannabis-dependent subjects. METHODS:Participants underwent an 8-week double-blind placebo-controlled trial (an ABACADAE design), with four smoke as usual conditions (SAU) (A) separated by four cannabis abstinence conditions (B-E), with administration of either self-titrated/fixed doses of placebo or Sativex (up to 108 mg THC/100 mg CBD). The order of medication administration during abstinence conditions was randomized and counterbalanced. Withdrawal symptoms and craving were assessed using the Cannabis Withdrawal Scale (CWS), Marijuana Withdrawal Checklist (MWC) and Marijuana Craving Questionnaire (MCQ). Medication use was assessed during the study by means of self-reports, vial weight control, toxicology and metabolite analysis. Cannabis use was assessed by means of self-reports. RESULTS: High fixed doses of Sativex were well tolerated and significantly reduced cannabis withdrawal during abstinence, but not craving, as compared to placebo. Self-titrated doses were lower and showed limited efficacy as compared to high fixed doses. Participants reported a significantly lower "high" following Sativex or placebo as compared to SAU conditions. Cannabis/medication use along the study, as per self-reports, suggests compliance with the study conditions. CONCLUSIONS: The results found in this proof of concept study warrant further systematic exploration of Sativex as a treatment option for cannabis withdrawal and dependence.
Authors: Deepak Cyril D'Souza; Walid Michel Abi-Saab; Steven Madonick; Kimberlee Forselius-Bielen; Anne Doersch; Gabriel Braley; Ralitza Gueorguieva; Thomas B Cooper; John Harrison Krystal Journal: Biol Psychiatry Date: 2005-03-15 Impact factor: 13.382
Authors: Kenneth H Levin; Marc L Copersino; Stephen J Heishman; Fang Liu; Deanna L Kelly; Douglas L Boggs; David A Gorelick Journal: Drug Alcohol Depend Date: 2010-05-26 Impact factor: 4.492
Authors: Jason P Connor; Daniel Stjepanović; Bernard Le Foll; Eva Hoch; Alan J Budney; Wayne D Hall Journal: Nat Rev Dis Primers Date: 2021-02-25 Impact factor: 52.329
Authors: Philip G Tibbo; Kyle A McKee; Jeffrey H Meyer; Candice E Crocker; Katherine J Aitchison; Raymond W Lam; David N Crockford Journal: Can J Psychiatry Date: 2020-09-11 Impact factor: 4.356
Authors: Jose M Trigo; Alexandra Soliman; Gregory Staios; Lena Quilty; Benedikt Fischer; Tony P George; Jürgen Rehm; Peter Selby; Allan J Barnes; Marilyn A Huestis; Bernard Le Foll Journal: J Addict Med Date: 2016 Jul-Aug Impact factor: 3.702
Authors: Matthew E Sloan; Caroline W Grant; Joshua L Gowin; Vijay A Ramchandani; Bernard Le Foll Journal: Acta Pharmacol Sin Date: 2018-08-30 Impact factor: 6.150